-
Sector Analysis
Graft versus Host Disease (GvHD): Epidemiology Report and Forecast to 2035
Graft-versus-host disease (GvHD) is a common and potentially serious complication that occurs after allogeneic hematopoietic stem cell transplantation (HSCT). HSCT is used as a potential cure for hematological cancers, syndromes of bone marrow failure, and congenital disorders of the hematopoietic system (Hymes, Alousi and Cowen, 2012; Passweg et al., 2025). GvHD occurs when the donor stem cells or the graft attack healthy cells in the patient or the host (Blood Cancer United, 2024). GvHD can damage a patient’s tissues and...
-
Thematic Analysis
Pharmaceutical Drug Development Annual Review 2025
This report investigates the year 2025 in the pharmaceutical industry from the standpoint of drug development. It provides a high-level analysis of key trends and movements within the industry via regulatory, clinical, and market-based analysis, allowing you to discern the large-scale changes and how best to pivot to prioritize them within your sector.
-
Thematic Analysis
Modality Intelligence - From Pipeline to Capital: Strategic Intelligence
Antibodies lead pipeline volume and forecast sales, and drive approvals alongside recombinants, but oligonucleotides are scaling fastest off a smaller base. Maturity and innovation stage, not pipeline size, determine where capital lands next. Capital is consolidating around modalities with proven commercial models, and the cost of entry into mAbs, ADCs, siRNA, and BsAbs is rising across M&A, licensing, and VC alike. Within mAbs and recombinants, capital is rotating out of mature mAb mega-deals and into early-stage ADC and recombinant platform...
-
Thematic Analysis
Pharma M&A Deals H1 2026 - Top Themes: Strategic Intelligence
This report analyzes the disruptive themes that have driven M&A activity in H1 2026 in the pharma Sector.
-
Product Insights
Respiratory Syncytial Virus (RSV) Infections: Global Clinical Trials Review, 2026
GlobalData's clinical trial report, “Respiratory Syncytial Virus (RSV) Infections - Global Clinical Trials Review, 2026" provides an overview of Respiratory Syncytial Virus (RSV) Infections Clinical trials scenario. This report provides top line data relating to the clinical trials on Respiratory Syncytial Virus (RSV) Infections. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end...
-
Product Insights
Hepatocellular Carcinoma: Global Clinical Trials Review, 2026
GlobalData's clinical trial report, “Hepatocellular Carcinoma - Global Clinical Trials Review, 2026" provides an overview of Hepatocellular Carcinoma Clinical trials scenario. This report provides top line data relating to the clinical trials on Hepatocellular Carcinoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Product Insights
Inflammatory Bowel Disease: Global Clinical Trials Review, 2026
GlobalData's clinical trial report, “Inflammatory Bowel Disease - Global Clinical Trials Review, 2026" provides an overview of Inflammatory Bowel Disease Clinical trials scenario. This report provides top line data relating to the clinical trials on Inflammatory Bowel Disease. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report...